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SUMMARY
Tumor- or cancer-associated fibroblasts (TAFs or CAFs) fromdifferent tumors exhibit distinct angiogenic and
tumorigenic properties. Unlike normal skin fibroblasts or TAFs from TIB6 tumors that are sensitive to anti-
VEGF treatment (TAF-TIB6), TAFs from resistant EL4 tumors (TAF-EL4) can stimulate TIB6 tumor growth
even when VEGF is inhibited. We show that platelet-derived growth factor C (PDGF-C) is upregulated in
TAFs from resistant tumors. PDGF-C-neutralizing antibodies blocked the angiogenesis induced by such
TAFs in vivo, slowed the growth of EL4 and admixture (TAF-EL4 + TIB6) tumors, and exhibited additive effects
with anti-VEGF-A antibodies. Hence, our data reveal an additional mechanism for TAF-mediated tumorigen-
esis and suggest that some tumors may overcome inhibition of VEGF-mediated angiogenesis through
upregulation of PDGF-C.INTRODUCTION
A variety of genetic/epigenetic changes within epithelial cells
that initiate neoplastic transformation and promote invasive
behavior and angiogenesis have been identified. In addition,
signaling resulting from interactions between epithelial cells
and stroma also contributes to tumor development (Bhowmick
and Moses, 2005; Bissell and Radisky, 2001; Kalluri and
Zeisberg, 2006; Red-Horse et al., 2007). Alterations in the stroma
can promote epithelial tumorigenesis (Barcellos-Hoff and
Ravani, 2000; Bhowmick et al., 2004; Maffini et al., 2004).
The stroma consists of extracellular matrix and mesenchymal
cell types, which are fibroblasts and myofibroblasts, various
inflammatory cells (Shojaei et al., 2008), endothelial cells, and
pericytes (Orimo and Weinberg, 2006). Similar to transformed
epithelial cells, tumor stroma may also exhibit drastic changes
at the transcriptional level (Allinen et al., 2004). Adding tumor-
associated fibroblasts (TAFs) to ‘‘initiated’’ but nontumorigenic
or malignant epithelial cells stimulates tumor growth and angio-
genesis in vivo (Olumi et al., 1999; Orimo et al., 2005). Orimo et al.
(2005) demonstrated that SDF-1, which is upregulated in tumorfibroblasts, stimulates tumor cell proliferation and angiogenesis.
TGF-b1 and HGF have been also implicated in the tumor-
promoting effects of TAFs (Bhowmick et al., 2004; Kuperwasser
et al., 2004). Moreover, a recent study has indicated that gene
expression signatures within the stroma can be useful prog-
nostic predictors of breast cancer progression (Finak et al.,
2008).
Fibroblasts are thought to promote tumor growth in part
through stimulation of tumor angiogenesis. One key mediator
of angiogenesis is vascular endothelial growth factor A (VEGF-A)
(Ferrara, 2004). VEGF-A has been also reported to promote
recruitment of bone marrow-derived cells (Grunewald et al.,
2006). Targeting VEGF-A, in combination with chemotherapy,
is efficacious in treating several human tumors (Ellis and Hicklin,
2008; Ferrara and Kerbel, 2005; Kerbel, 2008).
Platelet-derived growth factor C (PDGF-C) (Li et al., 2000) is
a member of the PDGF family (Aase et al., 2002; Andrae et al.,
2008; Ding et al., 2000; Fredriksson et al., 2004). PDGF-C
signaling through PDGF receptor (PDGFR) a and b homo- or het-
erodimers is important for the development of connective
tissues and for wound healing (Andrae et al., 2008; Li et al.,SIGNIFICANCE
Tumor-associated fibroblasts (TAFs) are active players in tumorigenesis. Here we show that TAFs may mediate resistance
to antiangiogenic therapywith VEGF inhibitors.We identified platelet-derived growth factor C (PDGF-C) as a keymediator of
TAF-induced angiogenesis. Blocking PDGF-C using specific antibodies reduces the growth of tumors that are resistant to
anti-VEGF treatment and exhibits additive effects with anti-VEGF therapies. Hence, our data indicate that targeting stroma-
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PDGF-C Mediates Angiogenic Properties of TAFs2000; Pietras et al., 2003). Recombinant PDGF-C stimulates
angiogenesis in chick embryos and mouse corneas (Cao et al.,
2002) and revascularizes ischemic tissues (Li et al., 2005).
PDGF-C has also been implicated as an autocrine growth regu-
lator of Ewing tumor cell lines in vitro (Zwerner and May, 2002).
Several studies have shown effects of TAFs on tumor growth
and angiogenesis, but it is unclear whether there are any
tumor-specific effects of TAFs. In this study, we examined
TAFs isolated from two types of tumors, one of which is sensitive
to anti-VEGF-A treatment and the other of which is refractory
(Shojaei et al., 2007a). Unlike normal skin fibroblasts (NSFs) or
TAFs from sensitive tumors, TAFs from refractory tumors can
promote in vivo growth of VEGF-sensitive tumors, even in the
presence of VEGF inhibitors. Our data indicate that PDGF-C is
upregulated in TAFs derived from refractory tumors and that
PDGF-C, together with VEGF-A, mediates the angiogenesis
induced by such TAFs in vivo. This study also demonstrates
that inhibition of PDGF-C may reduce tumor angiogenesis and
growth in vivo.
RESULTS
Isolation andCulture of Primary Fibroblasts fromNormal
Skin and Subcutaneous Tumors
TAFs were isolated from EL4 (TAF-EL4) and TIB6 (TAF-TIB6)
tumors of 1000 mm3 in size. EL4 tumors are refractory to
Figure 1. TAF-EL4 Promote TIB6 Tumor Growth in the
Absence or Presence of VEGF Inhibition
(A) Addition of TAF-EL4, but not normal skin fibroblasts (NSFs)
or TAF-TIB6, to TIB6 tumors promotes TIB6 tumor growth in
anti-ragweed-treated animals (*p < 0.0001, TAF-EL4 group
versus NSF group; *p < 0.015, TAF-EL4 group versus TAF-
TIB6 group; #p = 0.23, NSF group versus TAF-TIB6 group).
Data are presented as % change in tumor volume relative
to TIB6-only control across several independent experiments
(n = 3, 2, and 5, respectively).
(B) Addition of TAF-EL4, but not NSFs or TAF-TIB6, to TIB6
tumors results in increased TIB6 tumor growth in anti-VEGF
mAb-treated animals (*p < 0.00005, TAF-EL4 group versus
NSF group; *p < 0.0018, TAF-EL4 group versus TAF-TIB6
group; #p = 0.08, NSF group versus TAF-TIB6 group). Data
reflect several independent experiments (n = 3, 2, and 6,
respectively).
(C) TAF-EL4-mediated tumorigenesis contains VEGF-depen-
dent and -independent mechanisms (*p < 0.05).
Data are shown as means ± SEM.
anti-VEGF treatment, whereas TIB6 tumors are
sensitive (Shojaei et al., 2007a) (see Figure S1 avail-
able online). All primary fibroblasts (NSFs, TAF-
EL4, and TAF-TIB6) exhibited spindle morphology
and expressed fibroblast surface protein (FSP)
(Figures S2A and S2B). B16F1 cells, in contrast,
did not express FSP. Primary fibroblasts were
also positive for a-smooth muscle actin (a-SMA)
(Figure S2C). Moreover, NSFs and TAFs (TAF-EL4
and TAF-TIB6) were largely negative for CD31
and CD45 expression (Figure S2D). Less than
0.3%, 0.3%, and 1% of cells were CD31 positive,
CD45 positive, or double positive respectively for all isolated
fibroblasts.
TAF-EL4 Promote TIB6 Tumor Growth Even
in the Presence of an Anti-VEGF Antibody
Both TIB6 and TIB6-GFP were employed for recombination
experiments. TIB6 and TIB6-GFP tumors exhibit similar
responses to anti-VEGF treatment, although the growth rate
of TIB6-GFP cells in mice is slower than that of TIB6 cells.
Xenografts containing only TIB6 cells were used as a control
and were implanted simultaneously with each admixture
group. The addition of NSFs or TAF-TIB6 to TIB6 tumors
did not alter TIB6 tumor growth (Figure 1A; Figures S3Aa
and S3Ab). In contrast, the addition of TAF-EL4 significantly
enhanced TIB6 tumor growth (Figures 1A and 1C; Figure S3Ac).
The increase in tumor mass was not due to EL4 tumor cell
contamination in the fibroblast preparation, since implants
containing only TAF-EL4 fibroblasts did not develop any
tumors (Figure 1C; Figure S3Ac). Furthermore, histological
analysis revealed only a minimal number of fibroblasts (Figure
S3Ad), indicating that increased tumor mass reflects the
growth of TIB6 tumor cells rather than TAF-EL4. Tumors
from all groups displayed histology similar to control TIB6
tumors (Figure S3Ad).
Similar in vivo recombination experiments were performed in
the presence of anti-VEGF monoclonal antibody (mAb). Neither
22 Cancer Cell 15, 21–34, January 6, 2009 ª2009 Elsevier Inc.
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PDGF-C Mediates Angiogenic Properties of TAFsNSFs nor TAF-TIB6 promoted TIB6 tumor growth when VEGF
was inhibited (Figure 1B; Figures S3Ba and S3Bb). In contrast,
addition of TAF-EL4 induced TIB6 tumor growth in the presence
of VEGF blockade (Figures 1B and 1C; Figure S3Bc). Admixture
of TIB6 and TAF-EL4 cells generated larger tumors (Figures
S3Bc and S3Bd) compared to TIB6 controls. Again, few fibro-
blasts were observed in the admixture tumors (Figure S3Be).
We also used TIB6-GFP tumor cells in recombination experi-
ments. GFP-labeled TIB6 cells were the predominant cell type
within the admixture tumors (Figure S3Bf). TAF-EL4-only
implants did not grow over the duration of the experiment
(Figure S3Bc). These findings argue against the possibility that
contaminating EL4 (GFP-negative) tumor cells contributed to
the growth of admixture tumors. VEGF-dependent mechanisms
are involved in TAF-EL4’s ability to promote TIB6 tumor growth,
since the growth of admixture tumors containing TAF-EL4 and
TIB6 cells was reduced by anti-VEGF antibodies (Figure 1C).
TAF-EL4 Are Not Different from TAF-TIB6 in Stimulating
TIB6 Cell Growth In Vitro
We cocultured TIB6 cells with NSFs, TAF-TIB6, or TAF-EL4
over a period of 3 days. TAF-EL4 did not perform better
Figure 2. TAF-EL4 Stimulate Tumor Angio-
genesis In Vivo
(A) TAF-EL4 are comparable to TAF-TIB6 in stimu-
lating TIB6 cell growth in vitro (#p = 0.58, TAF-EL4
versus TAF-TIB6; n = 4).
(B) Addition of TAF-EL4 to TIB6 tumors stimu-
lates tumor angiogenesis. Vascular density for
each admixture tumor was normalized to the
simultaneous TIB6 control tumors (*p < 0.0001,
TAF-EL4 group versus NSF group and TAF-
TIB6 group). Eight to fourteen fields were
analyzed for each group of tumors harvested at
day 26.
(C) TAF-EL4 and TIB6 admixture tumors exhibit
denser vascular networks than TIB6 control
tumors at day 26.
(Ca) Confocal images of TIB6 tumors and
TAF-EL4 and TIB6 admixture tumors. Scale
bars = 100 mm.
(Cb–Cg) Vasculature quantifications for control
TIB6 tumors and admixture tumors containing
TAF-EL4 and TIB6 cells. Entire TIB6 tumor
images and three random fields of the admixture
tumors were used for quantification.
(Cb) Number of branching points was deter-
mined by counting the intersection points (*p <
0.05).
(Cc) Average number of vessel segments per
field (*p < 0.05).
(Cd) Average segmental length per field (*p <
0.04).
(Ce) Average total vessel length per field (*p <0.02).
(Cf) Average total vessel area per field (*p <
0.005).
(Cg)Average total vessel volumeperfield (*p<0.02).
Data shown are means ± SEM.
than NSFs or TAF-TIB6 in stimulating
TIB6 proliferation in vitro (Figure 2A).
Similarly, no difference was observed
among various fibroblasts (NSFs or TAFs) in stimulating EL4
proliferation (Figure S4).
TAF-EL4 Promote Tumor Angiogenesis in the Presence
of VEGF Blockade
We performed CD31 immunostaining in multiple sections from
tumors with the largest andmedian sizes in all groups. Admixture
tumors containing TAF-EL4 and TIB6 cells exhibited extensive
vascular networks (Figures 2B and 2C; Figure S5). Themicrovas-
cular density in TIB6 and TAF-EL4 admixture tumors was 2-fold
higher than that in TIB6 control tumors (Figure 2B). In contrast,
the vascular networks in admixture tumors containing NSFs or
TAF-TIB6 and TIB6 cells were similar to those of the simulta-
neously harvested TIB6 control tumors.
We analyzed 80 mm tumor sections by confocal microscopy
and reconstructed 3D images. We measured the number of
vessel branching points, number of vessel segments, segment
length, total vessel length, vessel area, and vessel volume for
TAF-EL4 and TIB6 admixture tumors and control TIB6 tumors.
Addition of TAF-EL4 fibroblasts to TIB6 tumors led to a marked
increase (6-fold) in the number of vessel branching points
(Figure 2Cb) and segmental vessels (6 fold) (Figure 2Cc) and
Cancer Cell 15, 21–34, January 6, 2009 ª2009 Elsevier Inc. 23
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but increased total vessel length (>3-fold) (Figure 2Ce), vessel
area (2.5-fold) (Figure 2Cf), and vessel volume (2.5-fold)
(Figure 2Cg) per field. We did not observe any difference in
percent vessel coverage by PDGFRb+ cells between TAF-EL4
and TIB6 admixture tumors and control TIB6 tumors (72.6% ±
1.95 and 74.5% ± 2.15, respectively). We observed, however,
that many PDGFRb+ cells were also dispersed throughout TIB6
tumors, whereas themajority of PDGFRb+ cells within the admix-
ture tumors were associated with vessels (Figure 2C).
TAFs from Anti-VEGF-Refractory Tumors Induce
Angiogenesis In Vivo
We injected fibroblasts in growth factor-deprived Matrigel
subcutaneously into mice and allowed vessels to develop for
10 days. All primary fibroblasts (NSFs, TAF-TIB6, and TAF-
EL4) expressed PDGFRb as assessed by flow cytometry (data
not shown). Matrigel plugs without fibroblasts did not contain
any CD31- or PDGFRb-positive cells (Figure 3A), suggesting little
or no vessel formation and minimal invasion by host fibroblasts
or pericytes. Very few vessels were observed in Matrigel plugs
containing NSFs or TAF-TIB6. However, PDGFRb-positive cells
were present within the implants, suggesting the survival of the
implanted fibroblasts. In contrast, TAF-EL4 implants contained
a well-developed microvasculature that was supported by
PDGFRb-positive cells (Figures 3A and 3C). CD31-positive areas
within Matrigel only, NSFs, TAF-TIB6, and TAF-EL4 implants
amounted to 0.004%, 0.13%, 0.35%, and 10%, respectively
(Figure 3B).
TAFs from two additional tumors refractory to anti-VEGF treat-
ment, TIB42 and TIB48 (Figure S1), were able to induce angio-
genesis in Matrigel plug assays (Figures 3C and 3D). We also
isolated TAFs from GFP-positive EL4 and TIB6 tumors.
However, only TAF-EL4 were able to induce angiogenesis
in vivo (Figure 3E). No GFP-positive tumor cells were present in
the implants, whereas such cells were readily observed in the
positive controls. Similar experiments were also carried out
using TAF-TIB48 from TIB48-GFP tumors. Again, TAF-TIB48
alone induced angiogenesis in vivo without contaminating
TIB48-GFP cells (Figure 3D, left panel). These data indicate
that the angiogenesis we observed in TAF-EL4 or TAF-TIB48
implants was due to signals from TAF-EL4 or TAF-TIB48 cells,
not from contaminating tumor cells.
The onset of angiogenesis involves invasion of tip cells,
followed by stalk endothelial cells, to populate avascular areas
(Davis and Senger, 2005; Gerhardt and Betsholtz, 2005). Close
examination of vessels within TAF-EL4 implants at high magnifi-
cation (403) revealed that many CD31-positive endothelial cells
possessed tip-cell-like phenotypes (i.e., multiple cytoplasmic
extensions) (Figure 3F).
TAF-EL4 Express Higher Levels of VEGF-A,
but Not SDF-1, In Vivo
We measured VEGF concentrations in NSFs, TAF-TIB6, and
TAF-EL4 both in vitro and in vivo. TAF-TIB6 and TAF-EL4
secreted higher levels of VEGF than NSFs in vitro (Figure 4A).
However, VEGF levels in TAF-EL4 or TAF-TIB6 conditioned
media were similar. We then measured VEGF from fibroblast
implant lysates. Unlike the in vitro data, VEGF levels were highest24 Cancer Cell 15, 21–34, January 6, 2009 ª2009 Elsevier Inc.in the TAF-EL4 groups (Figure 4B). TAF-TIB6 in vivo implants
contained the lowest amounts of VEGF (50 pg/ml). These
data suggest that VEGF might partially account for the ability
of TAF-EL4 to induce angiogenesis. However, NSF implants,
which exhibit only 2-fold lower VEGF production, did not induce
any microvascular sprouting, suggesting that one or more addi-
tional factors produced by TAF-EL4 cooperate with VEGF to
stimulate angiogenesis.
It has been reported that TAFs promote tumor growth via up-
regulation of SDF-1 (Orimo et al., 2005). However, we found
reduced levels of SDF-1 in TAF-EL4 and TAF-TIB6 implants
compared to NSF implants (Figure 4C), suggesting that the
angiogenesis observed in TAF-EL4 implants is not mediated by
SDF-1.
PDGF-C Is Upregulated in TAFs from Refractory Tumors
We compared gene expression profiles of TAFs from resistant
versus sensitive tumors by microarray analysis. Unsupervised
clustering analysis of genes that exhibited statistically significant
changes revealed a pattern that clearly separated TAFs of resis-
tant tumors (TAF-EL4, TAF-TIB42, and TAF-TIB48) from NSFs
and TAF-TIB6 (Figure 5A). Microarray analysis (and subsequent
TaqMan analysis) revealed that PDGF-C, Angptl2,HOX-A10 and
A7, andCOX-2were among the upregulated genes in TAFs from
resistant tumors. The complete data set is available at the NCBI
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/)
with the accession number GSE13549.
We focused our analysis on secreted or cell surface proteins.
Among the genes that demonstrated reproducible changes
across multiple probes included in the microarray chip, PDGF-C
was consistently upregulated in TAFs from three different resis-
tant tumors. While all TAFs exhibited higher PDGF-C expression
than NSFs did, expression of PDGF-C was highest in TAFs
from resistant tumors (Figure 5B). Surprisingly, we observed
a downregulation of SDF-1 in TAFs from refractory tumors
(Figure 5C).
We also dissociated TIB6 and EL4 tumors and flow-sorted
cells into four different populations: tumor cells (GFP+), enriched
fibroblasts (GFPCD31CD45), endothelial cells (GFPCD31+
CD45), and bone marrow-derived cells (including resident
macrophages) (GFPCD31CD45+). TaqMan analysis on such
freshly isolated cells indicated that all cell types within TIB6
tumors had minimal PDGF-C expression (Figure 5D). Cells
from EL4 tumors exhibited elevated levels of PDGF-C compared
to those in TIB6 tumors, the highest expression being observed
in enriched fibroblasts.
VEGF and PDGF-C Are Required for TAF-Induced
Angiogenesis In Vivo
To determine whether the angiogenesis induced by TAF-EL4
requires VEGF-A, we treated the animals harboring the implants
with anti-VEGF mAb for 30 days. We observed some vessels in
TAF-EL4 implants treated with anti-VEGF. However, when
compared to the control antibody-treated group, vascular densi-
ties were markedly reduced (Figure 6A; Figure S6), indicating
that VEGF is required for the full angiogenic response.
We next asked whether PDGF-C is required for TAF-EL4-
induced angiogenesis. We used a neutralizing affinity-purified
anti-mPDGF-C IgG. Western blot analysis demonstrated that
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PDGF-C Mediates Angiogenic Properties of TAFsthis antibody interacted strongly with mouse or human PDGF-C
but had no detectable interaction with PDGF-A, PDGF-B,
PDGF-D, or VEGF-A (Figure S7). In addition, the antibody specif-
ically neutralized PDGF-C-induced endothelial cell migration
(see below).
TAF-EL4 fibroblastsmixedwith PBS, goat IgG, or anti-PDGF-C
IgG were implanted subcutaneously. Addition of anti-PDGF-C
IgG to TAF-EL4 implants significantly delayed the angiogenic
response (Figures 6B and 6C). There was >6-fold reduction in
normalized vascular density in TAF-EL4 implants containing
anti-PDGF-C antibody as compared to TAF-EL4 implants
containing goat IgG (Figure 6C). The requirement for PDGF-C
in TAF-induced angiogenesis was not limited to TAF-EL4, since
similar results were obtained with TAF-TIB42 cells (data not
Figure 3. TAFs from Anti-VEGF-Refractory Tumors Induce In Vivo Angiogenesis in Matrigel Plug Assays
(A) TAF-EL4-induced angiogenesis in vivo. Scale bars = 100 mm.
(B) CD31-positive areas in Matrigel implants (*p < 0.01, TAF-EL4 versus TAF-TIB6; n = 5–6). Data are shown as means ± SEM.
(C) Overviews of TAF-EL4- and TAF-TIB42-induced angiogenesis in Matrigel plugs. Images shown here contain the entire Matrigel plugs and are tiled pictures of
25 or 49 images taken at 103, respectively. Scale bars = 200 mm.
(D) TAF-TIB48 are able to induce angiogenesis in vivo. As a positive control, TAF-TIB48 were mixed with TIB48-GFP tumor cells prior to implantation (right panel).
Scale bars = 100 mm.
(E) TAF-EL4-induced angiogenesis does not result from EL4 tumor cell contamination. TAF-TIB6 and TAF-EL4 fibroblasts were isolated from TIB6-GFP and
EL4-GFP tumors, respectively. No GFP-positive tumor cells were observed in either TAF-TIB6- or TAF-EL4-only implants. GFP-positive tumor cells were
used as positive control. Scale bars = 100 mm.
(F) Cells with tip-cell-like phenotypes were observed in TAF-EL4-only implants. Scale bars = 50 mm.
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PDGF-C Mediates Angiogenic Properties of TAFsshown). Incubation of TAF-EL4 or TAF-TIB42 with anti-PDGF-C
did not affect TAF viability (Figure S8), indicating that the reduc-
tion in vascular density resulting from anti-PDGF-C was not due
to impaired TAF viability.
Conversely,weadded recombinant PDGF-C tononangiogenic
TAF-TIB6 inMatrigel plugs.While TAF-TIB6 alonewere unable to
induce angiogenesis, addition of PDGF-C (3.3 mg) led to an
increase in vascular density compared to control (Figures 6D
and 6E). SDF-1 (3.3 mg), a cytokine that has been shown to
induce angiogenesis in other biological settings, did not induce
such effects under the conditions tested (Figures 6D and 6E).
Anti-PDGF-C Antibodies Suppress the Growth of EL4
and TAF-EL4 Admixture Tumors and Are Additive
with Anti-VEGF Antibodies
Addition of TAF-EL4 to TIB6-GFP tumor cells promoted TIB6
tumor growth in both anti-ragweed- and anti-VEGF-treated
groups (Figure 7A). Single-agent treatment of admixture tumors
with anti-PDGF-C IgG resulted in 63% growth inhibition at day
20 relative to goat IgG (Figure 7A; Figure S9).Moreover, combina-
tionof anti-PDGF-Candanti-VEGFantibodies further reduced the
Figure 4. VEGF-A, but Not SDF-1, Is Upregulated in TAF-EL4
Implants
(A) VEGF-A concentrations in conditioned media (#p = 0.63, TAF-EL4 versus
TAF-TIB6; n = 3 independent experiments).
(B) VEGF concentrations in lysates from Matrigel implants (*p < 0.05, TAF-EL4
versus NSF implants; n = 4 each).
(C) SDF-1 concentrations in Matrigel lysates (*p < 0.003, TAF-EL4 versus NSF
implants; #p = 0.38, TAF-EL4 versus TAF-TIB6 implants; n = 4 each).
Data are shown as means ± SEM.26 Cancer Cell 15, 21–34, January 6, 2009 ª2009 Elsevier Inc.growth of admixture tumors compared tomonotherapy with anti-
VEGFmAb. By day 34, the combination resulted in74%growth
inhibition compared to anti-VEGF alone. We next tested the effi-
cacy of anti-PDGF-C antibodies on growth of EL4 tumors. Anti-
PDGF-C IgG reduced thegrowthof EL4 tumorsby32%(Figures
7Ba and 7Bd). A comparable degree of inhibition (37%) was
achieved using anti-VEGF mAb (Figures 7Bb and 7Bd). Greater
inhibition (62%) was observed in animals treated with both
anti-PDGF-C and anti-VEGF antibodies (Figures 7Bc and 7Bd).
In contrast, anti-PDGF-C IgG had no effect on TIB6 tumor
growth (Figure 7Ca), whereas anti-VEGF mAb resulted in
a dramatic inhibition (Figures 7Cb and 7Cd). These findings are
consistent with the minimal expression of PDGF-C in TAFs or
other cell fractions from TIB6 tumors (Figure 5D).
PDGF-C Induces Migration of Endothelial Cells,
but Not of CD11b+Gr1+ Cells
To identify the potential target (or targets) of PDGF-C, we
analyzed the expression levels of PDGFRa and b in different
cell populations within TIB6 and EL4 tumors. In addition to
PDGF-C, PDGFRa and b were upregulated in enriched fibro-
blasts, endothelial cells, and bone marrow cells within EL4
tumors (Figure 8A). Since previous studies (Shojaei et al.,
2007a) demonstrated that tumor infiltration by CD11b+Gr1+
myeloid cells, which also express CD45, can facilitate tumor
growth in the presence of anti-VEGF antibodies, we tested
whether PDGF-C might recruit CD11b+Gr1+ myeloid cells.
CD11b+Gr1+ cells isolated from bone marrow of TIB6 or EL4
tumor-bearingmice expressed very low levels of PDGF-C recep-
tors (Figure 8A). Accordingly, PDGF-C did not induce the migra-
tion of myeloid cells (Figure 8B). However, SDF-1 strongly
induced migration of these cells. Moreover, PDGF-C did not up-
regulate any proangiogenic genes tested (VEGF-A and B, PLGF,
HGF, FGF2, PDGF-A, -B, and -C,Angpt2,Angptl1 and 2,MMP9,
and MMP13) in CD11b+Gr1+ cells (data not shown).
While mesenchymal cells are PDGF-C’s primary target,
PDGF-C can also inducemigration ofmouse endothelial progen-
itors and human endothelial cells (Li et al., 2005). Endothelial
cells within EL4 tumors expressed PDGFRs, raising the possi-
bility that the PDGF-C-mediated angiogenesis we observed
could be explained at least in part by its direct effect on endothe-
lial cells. We isolated and cultured primary mouse endothelial
cells (mECs) from normal lungs. mECs expressed mRNAs for
PDGFRa and b (Figure 8A), VEGFRs, and other endothelial cell
specific markers (Figures S10 and S11). VEGF-A induced mEC
migration in vitro (Figure 8Ca). PDGF-C induced migration of
mECs comparable to VEGF (Figure 8Cb). Anti-PDGF-C IgG
specifically blocked mEC migration induced by PDGF-C,
whereas goat IgG had no inhibitory effects.
DISCUSSION
We chose murine lymphoma models for our study because
tumor-free TAFs could be easily isolated from these tumors,
providing a suitable and reproducible experimental system.
TAF-EL4, but not TAF-TIB6, were able to stimulate the in vivo
growth of the anti-VEGF-sensitive TIB6 tumor, suggesting
that signals from tumor cells can regulate TAF tumorigenic prop-
erties. Furthermore, TAF-EL4 can also stimulate TIB6 tumor
Cancer Cell
PDGF-C Mediates Angiogenic Properties of TAFsFigure 5. PDGF-C Is Upregulated in TAFs from Anti-VEGF-Resistant Tumors
(A) Clustering analysis for genes that exhibited statistically significant changes in TAFs from anti-VEGF-resistant tumors (EL4, TIB42, and TIB48) versus NSFs and
TAF-TIB6.
(B and C) PDGF-C (B) and SDF-1a (C) expression in NSFs, TAF-TIB6, TAF-EL4, TAF-TIB42, and TAF-TIB48 cells.
(D) PDGF-C expression in different cell types within TIB6 and EL4 tumors. Tumors (1000 mm3; n = 5 each) were sorted into four different populations based on
expression of GFP, CD31, and CD45: tumor cells (GFP+), enriched fibroblasts (GFPCD31CD45, pooled), endothelial cells (GFPCD31+CD45, pooled), and
bone marrow-derived cells (GFPCD31CD45+, pooled). Enriched fibroblasts from EL4 tumors expressed200-fold more PDGF-CmRNA than those from TIB6
tumors (*p < 0.0001). Data are shown as means ± SEM.growth even when VEGF signaling is inhibited, suggesting that
TAFs can modulate tumors’ responses to anti-VEGF therapy.
Our analysis revealed both VEGF-dependent and -independent
mechanisms for TAF-EL4-mediated tumor promotion. Other
studies investigating tumor resistance/refractoriness to antian-
giogenic therapies with VEGF blockers have identified additional
potential mechanisms, including expression of alternative angio-
genic factors (Bergers and Hanahan, 2008; Fischer et al., 2007),
selection of hypoxia-resistant tumor cells (Yu et al., 2002), and
recruitment of myeloid cells (Shojaei et al., 2007a).
TAFs have been reported to upregulate CXCL14 and SDF-1
(CXCL12), which may directly stimulate tumor cell proliferation(Allinen et al., 2004; Orimo et al., 2005). However, in our study,
we did not find any evidence that TAF-EL4 potentiate tumor
growth by promoting tumor cell proliferation. Rather, TAF-EL4
were able to stimulate tumor angiogenesis. Interestingly, in
admixture tumors containing both TAF-EL4 and TIB6 cells, we
also observed a close association between PDGFRb-positive
cells and blood vessels, while in TIB6 control tumors, some
PDGFRb-positive cells were associated with vessels and some
were dispersed throughout the tumor. This observation suggests
that TAF-EL4, which also express PDGFRb, may be able to
support the survival and/or stability of newly formed vessels
when VEGF is inhibited. Furthermore, TAF-EL4 or TAFs isolatedCancer Cell 15, 21–34, January 6, 2009 ª2009 Elsevier Inc. 27
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(A) Anti-VEGF mAb impairs angiogenesis induced by TAF-EL4. Vessels were stained with anti-CD31 antibody, and images were taken at 103. Scale bars =
200 mm.
(B) Anti-PDGF-C IgG significantly reduces angiogenesis in TAF-EL4 Matrigel implants. Images shown here are tiled pictures of 20–120 images taken at 103.
Antibodies were administered once at the time of implantation (see Experimental Procedures). Three independent experiments were performed. Dotted line
marks the edge of Matrigel implants. Scale bars = 200 mm.
(C) Fold change in vascular density of implants containing control IgG or anti-PDGF-C IgG after normalization to the simultaneous PBS control implants (*p < 0.02;
n = 9 each). Data are shown as means ± SEM. Each mouse was implanted with twoMatrigel plugs with control PBS on the left flank and goat IgG or anti-PDGF-C
IgG on the right flank.
(D) Addition of PDGF-C, but not SDF-1, leads to angiogenesis in TAF-TIB6Matrigel implants. The images are tiled pictures of 30–90 images combined. Dotted line
marks the edge of implants. Scale bars = 500 mm.
(E) Fold change in vascular density of implants containing PDGF-C or SDF-1 versus controls (*p < 0.01; n = 6 each). Data are shown as means ± SEM.from other resistant tumors were able to induce angiogenesis
in vivo, demonstrating that the ability to induce such activity is
maintained regardless of the presence of tumor cells. These
data suggest that epigenetic and/or genetic modulations may
have occurred in such TAFs. In this context, previous studies
have reported genetic alterations in tumor-associated stromal
cells (Pelham et al., 2006). In other cases, epigenetic modula-
tions may be involved (Qiu et al., 2008). However, we did not
observe any statistically significant copy number gains or losses
in any fibroblasts used in this study (Figure S12).
VEGF-A is a major regulator of angiogenesis and is expressed
by fibroblasts (Dong et al., 2004). Therefore, it is possible that the
tumor-promoting effects of TAF-EL4 in animals treated with anti-
VEGF result at least in part from upregulation of VEGF-A. In vivo,
VEGF-A concentrations were highest in TAF-EL4 implants. VEGF
was indeed important for angiogenesis, since treatment with
anti-VEGF antibodies significantly reduced CD31-positive areas
in such implants. However, the concentrations of VEGF in TAF-
EL4 implants were low and only about 2-fold higher than that
in NSF implants, which did not trigger any angiogenesis. This
observation, together with the finding that 5 mg/ml of VEGF alone
did not induce angiogenesis in the Matrigel plug assay over the28 Cancer Cell 15, 21–34, January 6, 2009 ª2009 Elsevier Inc.same time period (data not shown), suggests that one or more
other factors from TAF-EL4 synergize with VEGF. SDF-1 has
been characterized as a mediator of TAF-induced tumor angio-
genesis (Orimo et al., 2005). However, in our system SDF-1
does not appear to be involved, highlighting the complexity
and multiplicity of pathways that regulate angiogenesis.
Our analysis shows that fibroblasts from EL4 tumors upregu-
late PDGF-C compared to fibroblasts from TIB6 tumors. The
largest difference was observed when comparing freshly iso-
lated fibroblasts from EL4 and TIB6 tumors. Among different
cell populations within EL4 tumors, fibroblasts expressed the
highest level of PDGF-C mRNA. Moreover, PDGFRa and
b were upregulated in fibroblasts, endothelial cells, and bone
marrow-derived cells from EL4 tumors, suggesting possible au-
tocrine and paracrine effects of PDGF-C during EL4 tumor
progression. The receptors for PDGF-C, PDGFRa and b, (Cao
et al., 2002), have been detected in various cell types including
endothelial precursor cells, tumor endothelial cells, pericytes,
and fibroblasts (Bergers et al., 2003; Dong et al., 2004; Marx
et al., 1994; Pietras et al., 2003; Rolny et al., 2006). Our data
point to tumor-specific upregulation of PDGFRa and b in
TAFs, endothelial cells, and bone marrow-derived cells.
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PDGF-C Mediates Angiogenic Properties of TAFsGiven that CD11b+Gr1+ myeloid cells have been shown to
confer refractoriness to anti-VEGF treatment (Shojaei et al.,
2007a), we examined the possibility that PDGF-C may recruit
and/or activate such cells. However, PDGF-C did not stimulate
migration of CD11b+Gr1+ cells from naive or tumor-bearing
animals, nor did it induce transcriptional upregulation of proangio-
genic genes. Consistent with these findings, CD11b+Gr1+ cells
expressed relatively low levelsofPDGFRaandb. Potentially, other
bone marrow-derived cell types within EL4 tumors that express
higher levels of PRGFR-a and b might respond to PDGF-C
signaling and contribute to PDGF-C-mediated tumorigenesis.
Unlike CD11b+Gr1+cells, endothelial cells demonstrated a
chemotactic response to PDGF-C, comparable to that induced
Figure 7. Effects of Anti-PDGF-C and Anti-
VEGF Antibodies on Tumor Growth
(A) Anti-PDGF-C IgG reduces growth of admixture
tumors as a single agent (*p < 0.006, 0.005, and
0.003, respectively; n = 10 each). Combination of
anti-PDGF-C and anti-VEGF antibodies induced
greater inhibition of admixture tumors than
anti-VEGF treatment alone (*p < 0.001, < 0.001,
and < 0.001, respectively; n = 10 for combination
treatment group, n = 5 for anti-VEGF-treated
group). Data for all control treatment groups are
included in Figure S9.
(Ba) Anti-PDGF-C IgG reduces EL4 tumor growth
in vivo (*p < 0.001 and p < 0.005, respectively;
n = 10 each).
(Bb) Anti-VEGF mAb reduces EL4 tumor growth
in vivo (*p < 0.001 and p < 0.0001, respectively;
n = 10 each).
(Bc) Combination of both anti-PDGF-C and
anti-VEGF blocking antibodies leads to a further
inhibition of EL4 tumor growth (*p < 0.0005 and
p < 0.0001, respectively; n = 10 each).
(Bd) Percent of tumor growth inhibition for single or
combination treatments (*p < 0.001, anti-PDGF-C
treatment group versus combination treatment
group; *p < 0.001, anti-VEGF treatment group
versus combination treatment group; #p = 0.42,
anti-PDGF-C treatment group versus anti-VEGF
treatment group).
(Ca) Anti-PDGF-C IgG has no effect on TIB6 tumor
growth (#p = 0.79 and 0.7, respectively; n = 10
each).
(Cb) Anti-VEGF mAb suppresses TIB6 tumor
growth (*p < 0.001; n = 10 each).
(Cc) Combination treatment does not further
reduce TIB6 tumor growth (*p < 0.001; n = 10
each).
(Cd) Percent of tumor growth inhibition for single
or combinational treatments at day 18 (*p <
0.0006, anti-PDGF-C treatment group versus
combination treatment group; #p = 0.93, combi-
nation treatment group versus anti-VEGF treat-
ment group).
Data are shown as means ± SEM.
by VEGF-A. These findings are also
consistent with other studies reporting
direct chemotactic effects of PDGF-C on
human endothelial cells (Li et al., 2005).
Together, these observations support
the hypothesis that PDGF-C can directly act on endothelial cells,
providing a rationale for its ability to promote angiogenesis.
Intriguingly, upregulation of PDGF-C occurs in several human
tumors (Lokker et al., 2002; Ostman and Heldin, 2001; Zwerner
and May, 2001), including pancreatic carcinomas (Genentech
Gene Logic analysis, data not shown). Pancreatic cancers are
enriched in fibroblastic stroma and have shown a very limited
response to most therapies, including combinations of anti-
VEGF antibodies and chemotherapy (Ellis and Hicklin, 2008; Fer-
rara and Kerbel, 2005; Kerbel, 2008). Ectopic expression of
PDGF-C in mice induces fibrosis and carcinogenesis (Campbell
et al., 2005). PDGF-C may also act directly on tumor cells to
promote their survival and/or proliferation (Lokker et al., 2002).
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stimulate EL4 tumor cell proliferation or migration in vitro
(Figure S13).
In this study, we demonstrate that an anti-PDGF-C neutral-
izing antibody can inhibit the angiogenic effects of TAFs isolated
from tumors refractory to anti-VEGF treatment. A combination
Figure 8. PDGF-C Stimulates Migration of Endothelial Cells, but Not of CD11b+Gr1+ Myeloid Cells
(Aa) Relative PDGFRamRNA levels. Enriched fibroblasts, endothelial cells, and bone marrow-derived cells in EL4 tumors express higher levels of PDGFRa than
their counterparts in TIB6 tumors (*p < 0.001, p < 0.001, and p < 0.001, respectively). mEC, mouse endothelial cells.
(Ab) Relative PDGFRbmRNA levels. Enriched fibroblasts, endothelial cells, and bone marrow-derived cells in EL4 tumors express higher levels of PDGFRb than
their counterparts in TIB6 tumors (*p < 0.001, p < 0.0001, and p < 0.009, respectively). X, undetectable levels.
(Ba and Bb) PDGF-C does not induce migration of CD11b+Gr1+ myeloid cells isolated from normal mice (Ba) or EL4 tumor-bearing mice (Bb).
(Ca) VEGF stimulates mEC migration (*p < 0.02, VEGF versus control media). Anti-VEGF mAb blocks VEGF-mediated mEC migration (*p < 0.004), whereas
anti-PDGF-C antibodies do not (#p = 0.2).
(Cb) PDGF-C inducesmECmigration (*p < 0.03, PDGF-C versus control). Anti-PDGF-C antibodies block PDGF-C-mediated mECmigration (*p < 0.036), whereas
control IgGs have no effect (#p = 0.4).
Data are shown as means ± SEM.
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PDGF-C Mediates Angiogenic Properties of TAFstherapy utilizing both anti-PDGF-C and anti-VEGF antibodies
was more effective than anti-VEGF treatment alone. However,
this combination did not completely block tumor growth, sug-
gesting that additional mechanisms are involved. Indeed, we
have previously reported that CD11b+Gr1+ myeloid cells stimu-
late tumor angiogenesis via another secreted protein, Bv8, and
contribute to tumor resistance to anti-VEGF treatment (Shojaei
et al., 2007a, 2007b). These findings suggest that, within the
same tumor, multiple molecular and cellular mechanisms result-
ing in VEGF-independent angiogenesis may coexist. While our
analysis here focused on PDGF-C, array data identified addi-
tional potential candidates such as Angptl2, which has been
implicated in angiogenesis (Oike et al., 2004). Whether Angptl2
plays a role in tumor refractoriness to anti-VEGF therapy remains
to be determined.
Previous studies suggested that a combination of VEGF
antagonists with PDGFR inhibitors, such as imatinib, might be
a particularly effective anticancer strategy (Bergers et al., 2003;
Erber et al., 2004; Jo et al., 2006). However, recent studies
suggest that such an approach is associated in some cases
with marked toxicity (Hainsworth et al., 2007). It is tempting to
speculate that a combination therapy utilizing a more selective
inhibition of the PDGF axis, such as that achieved by targeting
PDGF-C, may offer some advantages, at least in some circum-
stances.
In conclusion, we have demonstrated that activation of VEGF-
independent proangiogenic programs in TAFs is tumor specific.
Once activated by the tumor environment, TAFs can maintain
their ability to induce angiogenesis independent of tumor cells,
thus suggesting an irreversible process. We have also identified
PDGF-C as an important mediator of TAF-induced angiogenesis
and tumorigenesis in vivo.
EXPERIMENTAL PROCEDURES
Cell Lines
The EL4, TIB6 (J558), TIB42 (R1.1), and TIB48 (BW5147.G.1.4) cell lines were
purchased from the American Type Culture Collection and cultured in DMEM
supplemented with 10% fetal bovine serum.
Isolation and Culture of Normal or Tumor-Associated Fibroblasts
Normal skin fibroblasts (NSFs) were isolated from dorsal skin of beige/nude/
xid mice. Tumor-associated fibroblasts (TAFs) were isolated from tumors
reaching 1000 mm3 in size from the same genetic background. To generate
TAFs, 13 106 cells were injected subcutaneously into the dorsal flank of 8- to
10-week-old beige/nude/xid mice. Tissues were digested with RPMI with
0.037% hyaluronidase (Sigma), 1 mg/ml collagenase/dispase (Roche), 10%
FBS, and antibiotics for 1–2 hr at 37C. Dissociated cells were filtered through
both 100 mm and 40 mm filters. Washed filtrates were plated onto 1% gelatin-
coated plates and cultured in 10% FBS-containing medium in an atmosphere
of 3% O2. Suspension tumor cells were removed after vigorous washing or
flow sorting. All NSFs and TAFs used in this study had undergone fewer
than ten population doublings in culture.
TaqMan Analysis
All TaqMan primers used were from Applied Biosystems. All analyses were
carried out on a standard ABI 7500 machine using the SuperScript III Platinum
One-Step qRT-PCR Kit (Invitrogen) according to the manufacturer’s recom-
mended protocols.
Antibodies
Anti-VEGF-A mAb G6-31 was derived from human Fab phage libraries (Liang
et al., 2006). The variable domains were grafted into themurine IgG2a constantdomain. The ability of mAb G6-31 to potently neutralize mouse or human
VEGF-A in vitro and in vivo has been previously documented (Gerber et al.,
2007; Yu et al., 2008). Anti-ragweed mAb was used as a control for mAb
G6-31 (Liang et al., 2006). Neutralizing, affinity-purified anti-mPDGF-C goat
IgG was purchased from R&D Systems (AF1447). Goat IgG was used as a
control.
Western Blot
Human and murine PDGF-C (R&D Systems), murine VEGF-A164 (R&D
Systems), human VEGF-A165 (Genentech, Inc.), murine PDGF-A and PDGF-B
(Antigenix America Inc.), and human PDGF-D (R&D Systems) were loaded
into duplicate 4%–20% SDS-PAGE (Invitrogen). All proteins were purified
from E. coli, except murine VEGF-A, which was expressed in insect cells.
Five hundred nanograms of each protein was loaded. PVDF membranes
were then incubated overnight with 0.2 mg/ml anti-mouse PDGF-C IgG (R&D
Systems, AF1447) or with 10 mg/ml mAb G6-31. The blots were incubated
with ImmunoPure HRP-conjugated rabbit anti-goat IgG or goat anti-mouse
IgG (Pierce) at a dilution of 1:10,000 and detected using a western blotting
detection system (GE Healthcare Bio-Science).
Immunohistochemistry and Flow Cytometry
Live NSFs and TAFs were stained with FITC- or APC-conjugated anti-CD45
and anti-CD31 antibodies (BD Pharmingen). For a-SMA staining, cells were
fixed in 4% PFA prior to staining with FITC-conjugated a-SMA (Sigma). The
percentage of cells expressing CD45, CD31, and a-SMA was quantified using
flow cytometry.
In Vivo Recombination Experiments
Animal studies were approved by the Genentech animal care committee and
performed according to regulatory standards. 8 3 105 TIB6 tumor cells in
growth factor-deprived Matrigel (BD Biosciences) or admixtures of TIB6 cells
and NSFs or TAFs at a ratio of 1:2.5 were injected subcutaneously in 8- to 10-
week-old beige/nude/xid mice. Treatment with anti-ragweed or anti-VEGF-A
mAb G6-31 was initiated 48 hr after cell inoculation and was administered
once a week thereafter at a dose of 5 mg/kg. In vivo recombination experi-
ments were divided into three groups using NSFs, TAF-TIB6, or TAF-EL4.
Each group contained both control and anti-VEGF-treated arms.
In Vivo Matrigel Plug Assay
NSFs or TAFs were mixed with growth factor-deprived Matrigel and injected
subcutaneously in beige/nude/xid mice at a density of 2 3 106 cells/100 ml
of Matrigel. The Matrigel implants were cleared, harvested, and cryofrozen
at day 8 for detection of VEGF and SDF-1 levels and at day 10 for vascular
staining. In some cases, fibroblasts were mixed with control solutions, goat
IgGs (3.3 mg), anti-PDGF-C IgG (3.3 mg), recombinant PDGF-C (3.3 mg), or
SDF-1 (3.3 mg) prior to injection. Neutralizing anti-mouse PDGF-C IgG
(AF1447) and recombinant PDGF-C and SDF-1 were from R&D Systems.
PDGF-C stock solution contained 4 mM HCl. All control experiments for
PDGF-C contained the same amount of diluted HCl.
Coculture Studies
NSFs or TAFs were plated onto 1% gelatin-coated 24-well plates and cultured
under 3% O2. TIB6 and EL4-GFP cells were added to the fibroblast cultures,
which were in 1% FCS, the next day. The number of TIB6 or EL4 cells after
3 days of coculture was counted using a Z2 particle counter and size analyzer
(Beckman).
Vascular Staining in Cryofrozen Samples
Cryofrozen tumor tissues or Matrigel plugs were sectioned at 80 mm thickness.
Each slide contained two 80 mm sections that were at least 1000 mm apart in
the tumor samples. Slides were stained with primary antibodies including
hamster anti-mouse CD31 antibody (Chemicon), rat anti-mouse PDGFRb
antibody (eBioscience), or rabbit anti-mouse collagen IV antibody (Cosmo
Bio Co., Ltd.). Samples were then stained with secondary antibodies including
FITC-, Cy3-, or Cy5-conjugated goat anti-hamster or anti-rat from Jackson
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Vascular density was assessed by measuring CD31+ areas per field using
ImageJ software. To quantify vascular branching points, segmental length,
vessel length, vessel area, and vessel volume, 3D confocal images of the
vascular network were reconstructed (80 mm in depth) using FilamentTracer
and quantified using Imaris software. Each intersection of two or more
branches was identified automatically for quantifying the number of branching
points and vessel segments between intersections.
VEGF and SDF-1 Assays
VEGF concentrations were measured using a mouse VEGF ELISA kit (R&D
Systems) according to the manufacturer’s instructions. SDF-1 concentrations
were determined by ELISA (Genentech).
Microarray Experiments and Analysis
Microarray experiments were performed using Agilent Whole Mouse Genome
expression arrays using Agilent-recommended protocols. Universal mouse
reference RNA was applied in each array (Stratagene). Three replicates were
prepared for each sample. Raw ratio values were log2 transformed, and a
Cyber t test (Baldi and Long, 2001) was performed to identify probe sets differ-
entially expressed between all sensitive and all resistant samples.
In Vivo Tumor Growth Studies with Anti-PDGF-C or Anti-VEGF
Antibodies
Recombination experiments using TAF-EL4 and TIB6-GFP cells were carried
out as described above. 1 3 106 EL4 or TIB6 cells were injected subcutane-
ously. All treatments were initiated at day 2. Thirty micrograms of anti-PDGF-C
neutralizing IgG or control goat IgGs in 50 ml solutions was administrated every
2 days intratumorally, given the limited availability of such antibody. Anti-VEGF
mAb or anti-ragweed antibodies were administered every 6 days at 5 mg/kg
intraperitoneally.
Expression Analysis in Cells within TIB6 or EL4 Tumors
and in Primary Mouse Endothelial Cells
TIB6-GFP and EL4-GFP tumors (1000 mm3; n = 5 each) were dissociated
and sorted by flow cytometry into four populations of cells based on expres-
sion of GFP, CD31, and CD45. APC or FITC-conjugated anti-CD31 or CD45
antibodies were from BD Pharmingen. Primary mouse endothelial cells were
isolated from normal BALB/c mouse lungs using a MACS Cell Separation kit
(Miltenyi Biotec) according to the manufacturer’s protocol. CD45 beads
were used for negative selection, while CD31-FITC and anti-FITC beads
were used for positive selection. Cells were cultured in EGM-2MV growth
medium (Lonza) and were sorted again for CD31 expression. Postsorting anal-
ysis revealed that >99.5% of cells were CD31+. Gene expression analysis was
determined by TaqMan as described above.
In Vitro Migration Assays
Mouse endothelial and EL4 cells were exposed to EBM or DMEM media with
0.1% BSA and then plated onto either fibronectin-coated or noncoated upper
chambers (8 mm and 5 mm pore size, respectively) of migration assay plates
(BD Biosciences). CD11b+Gr1+cells were isolated from the bone marrow of
naive or EL4 tumor-bearing mice by flow cytometry. FITC- and PE-conjugated
anti-Gr1 and anti-CD11b antibodies were from BD Biosciences. Noncoated
inserts with 5 mm pore size were used for the experiment. Endothelial cells
that migrated across the upper chamber after 6 hr of cytokine stimulation
were stained with Sytox green nucleic acid stain (Invitrogen) and imaged.
Nuclei numbers were counted using ImageJ software. Numbers of migrated
EL4 and myeloid cells were determined using a Z2 particle counter and size
analyzer. Cytokines or serum were added to the bottom chambers; antibodies
or control IgGs were added to both chambers.
Array CGH
Agilent Mouse Genome CGH Microarray 244A was used for array CGH anal-
ysis according to Agilent-recommended protocols. Normal genomic DNA
was used as the control channel on all arrays (strain 000664, The Jackson
Laboratory). The resulting Agilent expression ratios were log2 transformed,
centered to a median of zero, and segmented using GLAD (Hupe et al.,32 Cancer Cell 15, 21–34, January 6, 2009 ª2009 Elsevier Inc.2004). All statistical analysis was performed using Partek software (Partek
Inc., version 6.08.0414).
Statistical Analysis
Statistical analysis was performed by t test except where otherwise noted in
figure legends or elsewhere in the Experimental Procedures.
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